GlassScriptPhysician profile
Hazel Jana Brewin
NPI 1376315242
$3,693.38
in general payments reported to CMS, 2019-2025
19 companies · $2,519 in 2025
The $2,519 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,175 · 2025: $2,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158 · Travel and Lodging: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.90 |
| Travel and Lodging | $535.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,015.28 | 2025 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $483.34 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.78 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $273.12 | 2024-2025 | Winrevair |
| Astrazeneca Pharmaceuticals LP | $261.17 | 2024-2025 | Farxiga, Wainua |
| United Therapeutics Corporation | $217.39 | 2024-2025 | Tyvaso, Orenitram, Remodulin |
| Bayer Healthcare Pharmaceuticals INC. | $204.65 | 2024-2025 | |
| Pfizer INC. | $186.21 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.56 | 2025 | Camzyos, Eliquis |
| Abiomed | $122.60 | 2025 | |
| Bridgebio Pharma, INC. | $98.20 | 2025 | Attruby |
| Medtronic, INC. | $90.91 | 2025 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.35 | 2024-2025 | Lifevest |
| Scpharmaceuticals INC. | $46.02 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $26.50 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $26.46 | 2024 | Arcalyst |
| Boston Scientific Corporation | $25.94 | 2025 | Watchman Flx |
| Novo Nordisk INC | $20.85 | 2024 | Ozempic |
| Impulse Dynamics (USA) INC. | $19.05 | 2024 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Brewin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.